Epacmarstobart
Based on 1 Customer Validation
Epacmarstobart (FSI-189; GS-0189) is an anti-SIRPα humanized antibody that blocks the CD47-SIRPα interaction. Epacmarstobart binds to human SIRPαV1 and SIRPαV2 with Kd values of 4.3 nM and 332 nM, respectively. Epacmarstobart enhances tumor cell phagocytosis in vitro in a SIRPα variant-dependent manner. Epacmarstobart can be used for research on non-Hodgkin lymphoma.
For research use only. We do not sell to patients.
- Purity : 99.33%
- CAS No.: 2518200-89-8
- Molecular Weight:144.94 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
SIRPa/CD172a
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Monocyte | EC50 |
0.024 μg/mL
|
Receptor occupancy on human CD14+ monocytes from healthy donors with SIRPαV1/V1 genotype assessed by free-receptor format using allophycocyanin-conjugated anti-human CD172ab antibody and mean fluorescence intensity.
Receptor occupancy on human CD14+ monocytes from healthy donors with SIRPαV1/V1 genotype assessed by free-receptor format using allophycocyanin-conjugated anti-human CD172ab antibody and mean fluorescence intensity.
|
37206279 |
| Monocyte | EC50 |
0.071 μg/mL
|
Receptor occupancy on human CD14+ monocytes from healthy donors with SIRPαV1/V2 genotype assessed by free-receptor format using allophycocyanin-conjugated anti-human CD172ab antibody and mean fluorescence intensity.
Receptor occupancy on human CD14+ monocytes from healthy donors with SIRPαV1/V2 genotype assessed by free-receptor format using allophycocyanin-conjugated anti-human CD172ab antibody and mean fluorescence intensity.
|
37206279 |
| Monocyte | EC50 |
2.44 μg/mL
|
Receptor occupancy on human CD14+ monocytes from healthy donors with SIRPαV2/V2 genotype assessed by free-receptor format using allophycocyanin-conjugated anti-human CD172ab antibody and mean fluorescence intensity.
Receptor occupancy on human CD14+ monocytes from healthy donors with SIRPαV2/V2 genotype assessed by free-receptor format using allophycocyanin-conjugated anti-human CD172ab antibody and mean fluorescence intensity.
|
37206279 |
In Vitro
Epacmarstobart occupies CD14+ monocytes from healthy donors in a SIRPα variant-dependent manner, with receptor occupancy (RO) EC50 values of 0.024 μg/mL for SIRPαV1/V1, 0.071 μg/mL for SIRPαV1/V2, and 2.44 μg/mL for SIRPαV2/V2[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of THP-1 cells labelling SIRPa (red) with Epacmarstobart (anti-SIRPa) (HY-P990019). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99991, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2518200-89-8
-
Appearance Liquid
-
Molecular Weight 144.94 kDa
-
Color Colorless to light yellow
-
SMILES
[Epacmarstobart]
-
Synonyms
FSI-189; GS-0189
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)